Expert Discusses How Negative Trial Impacted Field of mCRC
Cathy Eng, MD, discusses how the PRODIGE 7 trial, though negative, provided valuable evidence to the field for treatment of patients with metastatic colorectal cancer with peritoneal carcinomatosis.
Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses how the PRODIGE 7 trial, though negative, provided valuable evidence to the field for treatment of patients with metastatic colorectal cancer (mCRC) with peritoneal carcinomatosis.
This was the first trial in 15 years looking at treatment options for this patient population. While the results were negative, Eng says this is still an important trial because it highlighted the need to move forward in the field of mCRC.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
